

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Agilent launches NGS assay for advancing precision oncology

13 April 2023 | News

SureSelect Cancer CGP assay expands the number of biomarkers for solid tumour profiling with a fast and highly efficient workflow



US-based supplier of life sciences equipment and instruments Agilent Technologies Inc. has announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers. The assay workflow is efficient, automatable, and flexible, making tumor molecular profiling more accessible to the broad clinical research community.

The biomarkers include key classes of somatic variants (SNVs, CNVs, indels, translocations, de novo gene fusions), along with the immuno-oncology biomarkers TMB (tumor mutational burden), and MSI (microsatellite instability) to aid clinical and translational researchers in investigating potential cancer therapeutics.

Based on Agilent's industry-leading library prep and target enrichment chemistry, this high-performance assay provides up-to-date, globally curated biomarker content for comprehensive molecular profiling of solid tumors, supports as low as 10 ng of input, and incorporates walkaway automation to improve lab efficiency and productivity. The workflow incorporates flexible data analysis options, including Alissa Interpret for tertiary analysis and reporting, customer bioinformatics pipelines, and third-party software.